ANGPTL3 and type 2 diabetes mellitus: Our study showed reduced ANGPTL3 in patients with T2DM and diabetic mice after canagliflozin treatment for 12 weeks; moreover, we found the decreased expression of ANGPTL3 in the liver tissue in diabetic mice.